10:44 AM
 | 
Apr 05, 2019
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Black Diamond maps new class of glioblastoma mutations

Black Diamond showed in preclinical data presented at the American Association for Cancer Research (AACR) meeting why some EGFR mutations in glioblastoma multiforme (GBM) do not respond to early generation kinase inhibitors.

The mutations occur in the extracellular domain of...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >